|| List of recent Nucleotide-related patents
|Polypeptides having endoglucanase activity and polynucleotides encoding same|
Provided are isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Laser assisted delivery of functional cells, peptides and nucleotides|
The present invention relates to methods, uses, systems and kits for laser-assisted delivery of at least one bioactive agent to a subject. Specifically, laser light is used to create channel(s) in tissue of the subject, and the bioactive agent (s) is applied to the opening of the channel(s).
|Oligonucleotides for treating expanded repeat diseases|
The invention provides for a method for selectively reducing the expression of a mutant mrna and/or protein having an expanded nucleotide repeat relative to a wild-type mrna, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant huntington protein associated with huntington's disease.
|Antisense oligonucleotides against cpla2, compositions and uses thereof|
Antisense oligonucleotides against cpla2 are provided, which are capable of inhibiting cpla2 expression as well as superoxide production, especially in phagocytes. These antisense oligonucleotides are powerful agents for the treatment of inflammatory conditions, in particular arthritis, as well as in neurodegenerative diseases.
|Pharmaceutical composition comprising nanog shrna, and method of using nanog shrna to treat cancer|
The present description relates to an inhibitory rna molecule, comprising an oligonucleotide that selectively knocks down expression of either nanog or a nanog pseudogene, a vector capable of encoding such inhibitory rna molecule, pharmaceutical compositions comprising said vector, and methods of treating cancer by administration of said pharmaceutical composition.. .
|Cyclic nucleotide analogs|
Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs.. .
|Micro-utrophin polypeptides and methods|
Described herein are polypeptides, polynucleotides and methods involving a μ-utrophin region or an anti-dystrophinopathic fragment thereof operationally linked to a second region effective to transduce the fusion protein into mammalian muscle cells.. .
|Antisense antiviral compound and method for treating influenza viral infection|
The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal.
|Nucleic acid assembly system|
The present invention relates to a method for the preparation of a library of host cells, a plurality of which comprise an assembled polynucleotide at a target locus, which method comprises: (a) providing a plurality of polynucleotides comprising two or more polynucleotide subgroups, wherein: (i) a plurality of polynucleotides in each polynucleotide subgroup comprises sequence encoding a peptide or polypeptide and/or a regulatory sequence; (ii) a plurality of peptides or polypeptides encoded by, or a plurality of regulatory sequences comprised within, each polynucleotide subgroup share an activity and/or function; (iii) at least one polynucleotide subgroup comprises at least two non-identical polynucleotide species; (iv) a plurality of polynucleotides of each polynucleotide subgroup comprises sequence enabling homologous recombination with a plurality of polynucleotides from one or more other polynucleotide subgroups; and (v) a plurality of polynucleotides in two polynucleotide subgroups comprise a nucleotide sequence enabling homologous recombination with a target locus in host cells; and (b) assembling the plurality of polynucleotides at the target locus by homologous recombination in vivo in host cells, thereby to generate a library of host cells, a plurality of which comprise an assembled polynucleotide at the target locus. The assembled polynucleotides may be recovered, thereby to prepare a library of nucleic acids..
|Systems and methods for determining genetic data|
Systems and methods of polynucleotide sequencing are provided. Systems and methods optimize control, speed, movement, and/or translocation of a sample (e.g., a polynucleotide) within, through, or at least partially through a nanopore or a type of protein or mutant protein in order to accumulate sufficient time and current blocking information to identify contiguous nucleotides or plurality of nucleotides in a single-stranded area of a polynucleotide..
|Method for identifying aptamers|
The invention relates to a method for identifying aptamers, having the following steps bringing a mixture of oligonucleotides into contact with an aptamer target structure and binding at least some of the oligonucleotides to the target structure, separating the oligonucleotides which have been bound to the aptamer target structure from the aptamer target structure and from oligonucleotides that are not bound to the aptamer target structure, amplifying individual oligonucleotides which were bound to the aptamer target structure in a physically separate manner and producing a plurality of physically separate amplicons, each amplicon predominantly containing one type of oligonucleotides, specifying a specific marker for a plurality of the physically separate amplicons such that each of the marked amplicons can be uniquely identified using the specified marker of the amplicon, sequencing oligonucleotides in a plurality of marked amplicons and assigning the marker that is specific for the amplicon to the sequence of the type of oligonucleotides in the amplicon for each amplicon examined by means of the sequencing process analyzing the binding properties of the types of oligonucleotides to the aptamer target structure and assigning the analyzed binding properties to the specific markers of the amplicons and to the sequences of the types of oligonucleotides.. .
|Magnetic-nanoparticle conjugates and methods of use|
The present invention provides novel compositions of binding moiety-nanoparticle conjugates, aggregates of these conjugates, and novel methods of using these conjugates, and aggregates. The nanoparticles in these conjugates can be magnetic metal oxides, either monodisperse or polydisperse.
|Methods and processes for calling bases in sequence by incorporation methods|
Computer implemented methods, and systems performing such methods for processing signal data from analytical operations and systems, and particularly in processing signal data from sequence-by-incorporation processes to identify nucleotide sequences of template nucleic acids and larger nucleic acid molecules, e.g., genomes or fragments thereof.. .
|Colorectal cancer associated circulating nucleic acid biomarkers|
The invention provides methods and reagents for diagnosing colorectal cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated. In some embodiments, the cna biomarkers are polynucleotide fragments, e.g., dna fragments, that are present at an elevated level in blood, e.g., in a serum or plasma sample, of a colorectal cancer patient in comparison to the level in blood, e.g., a serum or plasma sample, obtained from a normal individual who does not have colorectal cancer..
|High throughput detection of molecular markers based on aflp and high through-put sequencing|
The present invention relates to a high throughput method for the identification and detection of molecular markers wherein restriction fragments are generated and suitable adaptors comprising (sample-specific) identifiers are ligated. The adapter-ligated restriction fragments may be selectively amplified with adaptor compatible primers carrying selective nucleotides at their 3′ end.
|Polydnavirus delivery constructs|
Provided herein are methods of producing a genetically modified cell by introducing a polydnavirus delivery construct to a target cell. The polydnavirus delivery construct can comprise an exogenous nucleic acid to form a genetically modified cell comprising the exogenous nucleic acid.
|Polymer based polynucleotide transfection agents|
The present invention provides a methodology for transfecting cells in vitro. In particular, cationic polymers and polynucleotide containing polyplexes comprising such polymers are provided..
|Chimeric double-stranded nucleic acid|
A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by rnase h when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive rna nucleotides.. .
|Variant cbh2 cellulases and related polynucleotides|
The invention provides variants of a streptomyces sp. Cbh2 that have improved properties compared to the wild type enzyme and methods of using the variants in the hydrolysis of substrates comprising cellulose..
|Variants of a family 44 xyloglucanase|
The present invention relates to variants of a parent xyloglucanase. The present invention also relates to polynucleotides encoding the variant xyloglucanases and to nucleic acid constructs, vectors, and host cells comprising the polynucleotide..
|Anti-idiotype antibody against anti-c-met antibody|
Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-met antibody, the use of the anti-idiotype antibody for detecting the anti-c-met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto.. .
|Rapid detection of the "high virulent" st-17 clone of group b streptococcus|
The present invention also relates to kits and methods for the specific detection of group b streptococcus highly-virulent st-17 clones, using the polynucleotides, the polypeptides or the antibodies according to the invention.. .
|Multimodal methods for simultaneous detection and quantification of multiple nucleic acids in a sample|
Described herein are approaches for the detection, identification, and/or quantification of target nucleic acids, including, but not limited to partially, substantially randomly, degraded target nucleic acids, in a biological sample, such as a formalin-fixed, paraffin-embedded (ffpe) sample. These approaches provide a means of detecting, identifying, and/or quantifying target nucleic acid molecules, including dna and rna molecules, further including rnas of different classes, from the same sample, and in the same reaction, by using “expander oligonucleotides,” as the term is defined herein, to convert fragments of target nucleic acids into discretely sized dna fragments, each with a chosen length characteristic for the target nucleic acid from which it is derived..
|Markers for susceptibility to an inhibitor of an src-family kinase|
The present invention relates to a method for predicting the responsiveness of a mammalian tumor cell or cancer cell to an inhibitor of a kinase of the src family, such as dasatinib, bosutinib, saracatinib or ponatinib. The present invention also provides for a method for predicting the responsiveness of an individual to an inhibitor of a kinase of the src family, whereby the individual is suspected to suffer from cancer.
|Porphyromonas gingivalis polypeptides and nucleotides|
The present invention relates to isolated porphyromanas gingivalis polypeptides and nucleotides. The polypeptides include an amino acid sequence selected from the group consisting of: seq.
|Live attenuated influenza virus|
Provided are live attenuated influenza a and b viruses as well as a composition, influenza a and b genes, a vector with a respective gene, a host cell comprising such vector, a method for preparing a live attenuated influenza a or b virus and a use of the influenza viruses as a vaccine. An influenza a virus contains a np-gene, which includes a silent mutation at one or more positions selected from nucleotide 1467, nucleotide 1473, nucleotide 1500, nucleotide 1503, nucleotide 1512, nucleotide 1515, nucleotide 1518, nucleotide 1521, and nucleotide 1524 of seq id no: 1.
|Novel pd1 isoforms, and uses thereof for potentiating immune responses|
In one embodiment, the present invention provides a new isoform of human pd1 (Δ42pd1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. Δ42pd1 does not engage pd-l1/pd-l2, and can induce the production of pro-inflammatory cytokines in one embodiment, Δ42pd1 can be used as an intramolecular adjuvant to develop a fusion dna vaccine for enhancing antigen-specific cd8+ t cell immunity and for prevention of pathogenic infection and/or cancer.
|Antibodies directed to angiopoietin-like protein 4 and uses thereof|
Antibodies directed to the antigen angptl4 and uses of such antibodies. In accordance with the teachings herein, there are provided fully human monoclonal antibodies directed to the antigen angptl4.
|Albumin binding antibodies and binding fragments thereof|
A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in seq id no: 1 or seq id no:2 and/or comprising a light chain variable domain having the sequence given in seq id no:3 or seq id no:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in seq id no: 1 and seq id no:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in seq id no: 2 and seq id no:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides.
|Predicting and diagnosing patients with systemic lupus erythematosus|
The present invention provides methods for the prediction and diagnosis of systemic lupus erythematosus using single nucleotide polymorphisms in irf8.. .
|Method and device for identifying nucleotide, and method and device for determining nucleotide sequence of polynucleotide|
The present invention provides technology that uses current measurements to identify nucleotides and determine a nucleotide sequence in polynucleotides. The present invention calculates a modal value of a tunnel current that arises when a nucleotide or polynucleotide for analysis passes through between electrodes, and then employs the calculated modal value.
|Dna detection methods for site specific nuclease activity|
The present disclosure provides methods for detecting and identifying plant events that contain precision targeted genomic loci, and plants and plant cells comprising such targeted genomic loci. The method can be deployed as a high throughput process utilized for screening the intactness or disruption of a targeted genomic loci and optionally for detecting a donor dna polynucleotide insertion at the targeted genomic loci.
|Nucleic acid agents for overexpressing or downregulating rna interference targets and uses of same in improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant|
A method of improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant is provided by expressing within the plant an exogenous polynucleotide encoding a polypeptide having an amino acid sequence at least 80% homologous to seq id nos: 687-981, 992-1248, 1281-1310, 1389-1391, and 2806-3081. Also provided is a method of improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plan by expressing within the plant an exogenous polynucleotide which downregulates an activity or expression of a polypeptide having an amino acid sequence at least 80% homologous to seq id nos: 311-514, 2007-2436, 1311-1320, 982-991, 1249-1280, 1321-1388.
|Isolated polynucleotides expressing or modulating dsrnas, transgenic plants comprising same and uses thereof in improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant|
A method of improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant is provided by expressing within the plant an exogenous polynucleotide at least 90% identical to seq id nos: 1-56, 62, 63, 110, 116, 117, 119-161, 200, 201-255, 1027-1031, 1459-1836. Also provided is a method of improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant by expressing within the plant an exogenous polynucleotide which downregulates an activity or expression of a gene encoding an rnai molecule having a nucleic acid sequence selected from the group consisting of seq id nos: 57-61, 64-115, 118, 162-200, 260-262, 265-267, 271, 1032-1455, 1810-1827, 1842-2265, 2620-2643, 2742-2792.
|Axmi205 variant proteins and methods of use|
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for pesticidal polypeptides are provided.
|Manipulation of dominant male sterility|
Compositions and methods for modulating male fertility in a plant are provided. Compositions comprise nucleotide sequences, and fragments and variants thereof, which modulate male fertility.
|Alpha-mannosidases from plants and methods for using the same|
The present invention is directed to alpha-mannosidase sequences from plants and the use thereof, especially genomic nucleotide sequences containing the regulatory elements controlling their expression, intron and exon sequences and polynucleotide sequences coding for alpha-mannosidase enzymes. Such plants with modified alpha-mannosidase activity can be used for the production of glycoproteins having an altered saccharide composition of great benefit.
|Protein having nuclease activity, fusion proteins and uses thereof|
The present invention relates to a nucleic acid molecule encoding (i) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of seq id no: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of seq id no: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of seq id no: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of seq id no: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein t is replaced by u; (ii) a fragment of the polypeptide of (i) having the activity of an endonuclease. Also, the present invention relates to a vector comprising the nucleic acid molecule and a protein encoded by said nucleic acid molecule.
|Mutant protease biosensors with enhanced detection characteristics|
A polynucleotide encoding a biosensor polypeptide comprising a modified circularly-permuted thermostable luciferase and a linker linking the c-terminal portion of the thermostable luciferase to the n-terminal portion of the thermostable luciferase. The modified circularly-permuted thermostable luciferase is modified relative to a parental circularly-permuted thermostable luciferase.
|Hepatitis b viral variants with reduced susceptibility to nucleoside analogs and uses thereof|
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis b virus (hbv) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies.
A novel class of pharmaceuticals which comprises a locked nucleic acid (lna) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties.
The present invention relates to a nucleic acid molecule containing a sequence of tricyclo nucleosides joined by internucleoside phosphorothioate linkage. The invention also relates to synthetic antisense oligonucleotides and to methods employing the same..
|Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites|
Provided herein are antisense oligonucleotides, compositions comprising antisense oligonucleotides, and methods for the use of antisense oligonucleotides in manipulating translation. Expression of isoforms of proteins expressed from different start codons of the same transcript are inhibited by antisense oligonucleotides, which may also enhance expression of non-target isoforms..
|Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a polynucleotide|
The present invention relates to the combinatorial use of an sirna targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression in the host of the protein encoded by the polynucleotide.. .
|Gene therapy for diabetic neuropathy using an hgf isoform|
The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of hgf or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of hgf.
|Protein-immobilizing solid phase, polynucleotide-immobilizing solid phase, and nucleic acid recovery method|
A protein-immobilizing solid phase is a protein-immobilizing solid phase comprising an mrna-nucleic acid linker-protein complex, obtained by linking the mrna and the protein encoded by that mrna through the nucleic acid linker, immobilized on the solid phase, wherein the nucleic acid linker has a photocleavage site and a solid phase binding site.. .
|Using populations of beads for the fabrication of arrays on surfaces|
The present invention provides methods for creating an array of features on a surface based on content transferred from a plurality of beads to the surface. Nucleic acid content can be transferred using a method including the steps of (a) providing a surface having one or more primer oligonucleotides attached to the surface; (b) providing a pool of beads, wherein beads in the pool have a plurality of templates attached thereto, the plurality comprising multiple copies of a single nucleic acid template sequence; (c) arraying the beads onto the surface by hybridizing the templates to the primer oligonucleotides; and (d) extending the primers to produce copies of the templates attached to the surface..
|Nucleic acid binding oligonucleotides|
The present application pertains to products and methods related to the ability of short nucleotide oligomers to bind the tertiary or globular structure of nucleic acids. This application discloses libraries of short oligomers and methods for using these libraries..
|Dna polymerase variants with reduced exonuclease activity and uses thereof|
Compositions and methods are described to modify family b dna polymerases that contain residual exonuclease activity that interferes with sequencing techniques and with detection of single nucleotide polymorphisms. The compositions are mutant proteins with reduced exonuclease activity compared with presently available “exo−” polymerases, and a sensitive screening assay that enables an assessment of exonuclease activity of any synthetic dna polymerase..
|Methods, systems, and computer readable media for evaluating variant likelihood|
A method for evaluating variant likelihood includes: providing a plurality of template polynucleotide strands, sequencing primers, and polymerase in a plurality of defined spaces disposed on a sensor array; exposing the plurality of template polynucleotide strands, sequencing primers, and polymerase to a series of flows of nucleotide species according to a predetermined order; obtaining measured values corresponding to an ensemble of sequencing reads for at least some of the template polynucleotide strands in at least one of the defined spaces; and evaluating a likelihood that a variant sequence is present given the measured values corresponding to the ensemble of sequencing reads, the evaluating comprising: determining a measurement confidence value for each read in the ensemble of sequencing reads and modifying at least some model-predicted values using a first bias for forward strands and a second bias for reverse strands.. .